Julen Oyarzabal Santamarina

This inventor holds 13 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 10 EPO patents, primarily in Biotechnology Innovations. Top assignees: Fundacion Para La Investigacion Medica Aplicada, Addex Pharma, S.a., Centro Nacional De Investigaciones Oncologicas (Cnio). Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julen Oyarzabal Santamarina. Retrieved from https://idiyas.com/inventor/julen-oyarzabal-santamarina

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 10)

% Patents Active = 53.8

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Olias del Rey (Toledo), ES (2012)
Toledo, ES (2014)
Madrid, ES (2014 - 2018)
Pamplona, ES (2016 - 2023)

Company Filing History:

5 out of 10

Fundacion Para La Investigacion Medica Aplicada

Centro Nacional De Investigaciones Oncologicas (Cnio)

patents

4. 2 out of 161

Janssen Pharmaceuticals, Inc.

patents

5. 1 out of 1

Fundación La Investigación Médica Aplicada

patent

6. 1 out of 2,103

Janssen Pharmaceutica Nv

patents

7. 1 out of 17

Proyecto De Biomedicina Cima, S.l.

patents

8. 1 out of 1

Tyris Therapeutics, S.L.

patent

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Closed Linear DNA

FOXP3-binding Peptides

DNA Methyltransferases

P13K Inhibitors

Cognition Improvement

Histone Methyltransferases

Phosphodiesterases

Antifibrinolytic Compounds

MGLUR2-receptors

Kinase Inhibitors

Substituted Pyrazinone Derivatives

MCH-1 Mediated Diseases

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12522864 - PROCESS FOR THE PRODUCTION OF CLOSED LINEAR DNA (2026-01-13),

2. 11560407 - FOXP3-binding peptides and uses thereof (2023-01-24),

3. 10654896 - FoxP3-binding peptides and uses thereof (2020-05-19),

4. 10407423 - Compounds as inhibitors of DNA methyltransferases (2019-09-10),

5. 9993554 - Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing (2018-06-12),

6. 9969744 - Compounds for use in cognition improvement (2018-05-15),

7. 9840500 - Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases (2017-12-12),

8. 9573956 - Compounds as dual inhibitors of phosphodiesterases and histone deacetylases (2017-02-21),

9. 9440989 - Antifibrinolytic compounds (2016-09-13),

10. 9266834 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2016-02-23),

11. 8841323 - 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors (2014-09-23),

12. 8778935 - Imidazopyrazines for use as kinase inhibitors (2014-07-15),

13. 8329704 - Substituted pyrazinone derivatives for use in MCH-1 mediated diseases (2012-12-11),

Title: Innovations of Julen Oyarzabal Santamarina

Introduction

Julen Oyarzabal Santamarina is a notable inventor based in Pamplona, Spain. He has made significant contributions to the field of medical research, particularly in the development of peptides that have potential applications in cancer treatment. With a total of seven patents to his name, his work is recognized for its innovative approach to addressing complex medical challenges.

Latest Patents

One of his latest patents is focused on FOXP3-binding peptides and their uses. The invention provides peptides of a specific general formula, which are designed to bind and inhibit FoxP3. These peptides are highly efficient in blocking Treg cell functionality, making them valuable in cancer treatment. The patent also includes constructs that comprise the peptide, as well as combinations that enhance its therapeutic potential.

Career Highlights

Throughout his career, Julen has worked with esteemed organizations such as Fundación para la Investigación Médica Aplicada and Fundación La Investigación Médica Aplicada. His work in these institutions has allowed him to advance his research and contribute to significant medical innovations.

Collaborations

Julen has collaborated with several professionals in his field, including Maria Obdulia Rabal Gracia and María Del Mar Cuadrado Tejedor. These collaborations have enriched his research and expanded the impact of his inventions.

Conclusion

Julen Oyarzabal Santamarina is a prominent inventor whose work in peptide research holds promise for cancer treatment. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.